Key Insights

Highlights

Treatment Research

8 treatments under study, led by Telaglenastat

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

3 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Terminated3

Clinical Trials (3)

Showing 3 of 3 trials
NCT05275673Phase 2Terminated

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

NCT04698681Terminated

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04265534Phase 2Terminated

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Showing all 3 trials

Research Network

Common Treatments

  • Telaglenastat1
  • Folic Acid 400 1000 Μg1
  • Vitamin B12 1000 Μg1
  • Dexamethasone1
  • Carboplatin1

Active Sponsors

  • Calithera Biosciences, Inc2
  • Faeth Therapeutics1

Top Investigators

Related Conditions

  • Nonsmall Cell Lung Cancer3
  • Nonsquamous Nonsmallcell Lung Cancer2
  • Keap1 Gene Mutation2
  • Nonsquamous Nonsmall Cell Neoplasm Of Lung2
  • Squamous Nonsmall Cell Neoplasm Of Lung1

Activity Timeline